Wealthfront Advisers LLC Grows Stock Position in Amgen Inc. $AMGN

Wealthfront Advisers LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 22.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,233 shares of the medical research company’s stock after purchasing an additional 12,857 shares during the period. Wealthfront Advisers LLC’s holdings in Amgen were worth $19,820,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. TAGStone Capital Inc. increased its stake in Amgen by 0.8% in the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock valued at $1,157,000 after purchasing an additional 32 shares in the last quarter. Wealth Quarterback LLC boosted its holdings in shares of Amgen by 1.6% during the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock worth $624,000 after purchasing an additional 34 shares during the last quarter. DDFG Inc lifted its holdings in shares of Amgen by 1.1% during the 3rd quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock worth $850,000 after acquiring an additional 34 shares during the period. Nicholson Wealth Management Group LLC boosted its holdings in Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after acquiring an additional 35 shares during the last quarter. Finally, Crown Wealth Group LLC raised its holdings in Amgen by 4.0% in the third quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock valued at $257,000 after buying an additional 35 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Down 3.0%

AMGN stock opened at $364.65 on Wednesday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a 50-day moving average of $335.74 and a two-hundred day moving average of $312.39. The stock has a market capitalization of $196.36 billion, a price-to-earnings ratio of 25.63, a price-to-earnings-growth ratio of 3.85 and a beta of 0.46. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $385.12.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the firm posted $5.31 EPS. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s dividend payout ratio is currently 66.90%.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AMGN. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price for the company. in a research note on Tuesday, January 20th. Oppenheimer set a $400.00 price target on Amgen and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Truist Financial lifted their price target on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Finally, Citigroup boosted their price objective on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $353.39.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.